» Articles » PMID: 2525320

Nicorandil As a Hybrid Between Nitrates and Potassium Channel Activators

Overview
Journal Am J Cardiol
Date 1989 Jun 20
PMID 2525320
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Nicorandil, although structurally a nitrate, differs from classic nitrates in several respects. It preferentially dilates resistive vessels. Its effect on venous return in dogs is not unanimously a decrease but rather an increase. In high doses or concentrations it suppresses myocardial contraction and ventricular automaticity, nearly sparing sinoatrial nodal automaticity and atrioventricular nodal conduction. It shortens the effective refractory period of myocardium. These cardiac effects of nicorandil have been explained by its mechanism of action as a potassium (K) channel activator. However, what part of the vascular effects of nicorandil this mechanism is responsible for has not been determined. BRL 34915 and pinacidil, nonnitrate vasodilators with a K-channel activator action, have essentially the same cardiovascular profile as nicorandil in isolated, blood-perfused canine heart preparations. In anesthetized, open-chest dogs the 2 K-channel activators decreased systemic blood pressure and increased venous return and cardiac output without elevating heart rate, unless the cardiodepressant effect emerged. The increase in venous return or cardiac output survived elimination of baroceptor functions. These results taken together with previous results on nicorandil suggest the following: (1) The property of nicorandil as a resistive vessel dilator highly selective for vasculature originates in its mechanism of action as a K-channel activator. The nonunanimous effect of nicorandil on venous return is a result of the opposing actions as a capacitive (action as a nitrate) and a resistive vessel dilator. Nicorandil, with its hybrid nature, is advantageous over specific K-channel activators and classic nitrates in therapeutic implications.

Citing Articles

Efficacy of Nicorandil in Preventing Myocardial Injury and Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta-Analysis.

Tariq H, Ahmed S, Ahmed S, Hanif N, Anwar E, Kumari A Cureus. 2024; 16(8):e66938.

PMID: 39280403 PMC: 11401642. DOI: 10.7759/cureus.66938.


A pilot study of perfusion balloon predilatation in conjunction with intracoronary nicorandil administration for acute coronary syndrome.

Yoshinaga M, Muramatsu T, Ishikawa M, Toriya T, Uwatoko T, Matsuwaki Y Cardiovasc Interv Ther. 2024; 40(1):45-56.

PMID: 39136888 DOI: 10.1007/s12928-024-01034-0.


Therapeutic potential of nicorandil beyond anti-anginal drug: A review on current and future perspectives.

Singh D, Singh R, Akindele A Heliyon. 2024; 10(7):e28922.

PMID: 38617945 PMC: 11015415. DOI: 10.1016/j.heliyon.2024.e28922.


An unusual case of thrombotic storm in an amateur cricketer-a case report.

Shankar T, Vempalli N, Bairwa A Int J Emerg Med. 2023; 16(1):65.

PMID: 37784022 PMC: 10544559. DOI: 10.1186/s12245-023-00539-4.


Pharmacotherapy in patients with vasomotor disorders.

Boerhout C, Feenstra R, van de Hoef T, Piek J, Beijk M Int J Cardiol Heart Vasc. 2023; 48:101267.

PMID: 37727753 PMC: 10505589. DOI: 10.1016/j.ijcha.2023.101267.